Compare Enveric Biosciences Inc (ENVB) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Main Street Capital Corporation — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Main Street Capital Corporation trades at $53.74 (market cap $5.09B). The key difference: Main Street Capital Corporation is far larger — about 748.5× Enveric Biosciences Inc's market cap, and Main Street Capital Corporation pays a 5.84% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Main Street Capital Corporation for 89 Days on average.
| ENVB | MAIN | |
|---|---|---|
Market Cap | $6.80M | $5.09B |
Volume | 64,867 | 524,060 |
Sector | Health | Financials |
52-Week High | $10.80 | $64.60 |
52-Week Low | $1.27 | $49.63 |
Typical Hold Time | 14 Days | 89 Days |
Enterprise Value | -$1.49M | $7.54B |
Dividend Yield | — | 5.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.52, up 1.67% with a bearish technical outlook despite recent earnings beats. The company shows no revenue but has improved quarterly EPS performance, with Q4 2025 turning positive. Analyst sentiment is bullish with 75% buy ratings, while technical indicators show selling pressure with 15 sell signals versus 1 buy.
Investment outlook remains speculative given negative profitability metrics and zero revenue, though patent developments and FDA guidance provide potential catalysts. Key risks include cash burn and clinical trial outcomes, while institutional support through financing offers near-term stability.
Main Street Capital (MAIN) trades at $54.47, showing modest daily gains of 0.54%. The stock faces bearish technical signals with resistance at $55 and support at $54. Fundamentally, MAIN maintains strong profitability with 80.77% net margins and trades at a reasonable P/E of 10.94. Recent earnings show mixed results with a Q2 beat but Q1 miss, while analysts maintain a cautious stance with 73% hold ratings.
The outlook remains balanced - MAIN's consistent dividend payments and strong ROE of 14.92% provide income appeal, but near-term earnings softness and premium valuation create headwinds. Key risks include declining revenue projections for 2026 and negative operating cash flow, requiring careful monitoring of portfolio performance in rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
